![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GE Duncan, HE Criswell, TJ McCown, IA Paul, RA Mueller and GR Breese
Biological Sciences Research Center, University of North Carolina, Chapel Hill.
Behavioral and neurochemical effects of haloperidol (D2-dopamine antagonist) and SCH-23390 (D1-dopamine antagonist) were examined in unlesioned rats and in rats lesioned with 6-hydroxy-dopamine (6-OHDA) as adults or as neonates. In unlesioned rats, chronic haloperidol treatment (15 days) resulted in an increase in D2-dopamine receptor density, as measured with [3H]spiperone, in the nucleus accumbens and in the caudate-putamen. Rats treated as adults with 6-OHDA responded to chronic haloperidol similarly to controls. However, adult rats treated with 6-OHDA as neonates did not exhibit an increase in [3H]spiperone binding in response to chronic haloperidol treatment. Control and adult 6-OHDA-treated rats given haloperidol exhibited a profound akinesia. In contrast, rats that received 6-OHDA as neonates and were tested as adults did not display a significant behavioral response to haloperidol at doses as high as 2 mg/kg. Results similar to those for haloperidol were also found for SCH-23390. Chronic treatment (15 days) with this D1- dopamine antagonist increased [3H]SCH-23390 binding in the nucleus accumbens and caudate-putamen in unlesioned rats as well as in adult 6- OHDA-treated rats. However, after neonatal 6-OHDA treatment, an elevation in [3H]SCH-23390 binding did not occur after chronic SCH- 23390 treatment. SCH-23390 produced akinesia similar to that produced by haloperidol in unlesioned and in adult 6-OHDA-treated rats. In contrast, rats lesioned with 6-OHDA as neonates and tested as adults did not exhibit a significant behavioral response to SCH-23390 under our test conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  J.N.D. Kerr and J. R. Wickens Dopamine D-1/D-5 Receptor Activation Is Required for Long-Term Potentiation in the Rat Neostriatum In Vitro J Neurophysiol, January 1, 2001; 85(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yokoyama and H. Okamura Self-Injurious Behavior and Dopaminergic Neuron System in Neonatal 6-Hydroxydopamine-Lesioned Rat: 1. Dopaminergic Neurons and Receptors J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1016 - 1030. [Abstract] [Full Text]
|
|
|
|
|
|
N.-Y. Huang, R. M. Kostrzewa, C. Li, K. W. Perry, and R. W. Fuller Persistent Spontaneous Oral Dyskinesias in Haloperidol-Withdrawn Rats Neonatally Lesioned with 6-Hydroxydopamine: Absence of an Association with the Bmax for [3H]Raclopride Binding to Neostriatal Homogenates J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 268 - 276. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Luthman, A. Fredriksson, A. Plaznik, and T. Archer Ketanserin and mianserin treatment reverses hyperactivity in neonatally dopamine-lesioned rats J Psychopharmacol, January 1, 1991; 5(4): 418 - 425. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
